differentia

Five Critical Decisions.One Best Asset

A successful drug is not one decision. It is the compounding effect of getting the critical decisions right.

Best Asset is the asset with the strongest combined probability of success, commercial potential, and value.

BEST
ASSET
Best Target
Best Molecule
Best Dosing
Best Trial Design
Best Segmentation

Invest Earlier in the Winners

Prioritize the assets with the strongest probability of success before major capital commitments.

Connect Every Decision

Carry mechanistic evidence from discovery through clinical development.

Build a Stronger Competitive Position

Identify the differentiation, patient population and development strategy most likely to win.

Create More Valuable Evidence

Build reusable, auditable evidence that strengthens development, regulatory and commercial decisions.

One Decision Engine. Across the Entire Drug Lifecycle.

01

Discovery

Find what is worth pursuing.

Best Target
02

Preclinical

Know what is worth testing.

Best Molecule
03

Translational

Bridge mechanism to human response.

Best Dosing
04

Clinical

Simulate the trial before committing patients.

Best Trial DesignBest Segmentation
Discovery

Best Target

For diseases without a faithful animal model, build from human evidence.

Human multi-omics enabled in silico disease model, for where mouse fails

Core Value

  • Multi-omics data integration
  • Target/MOA validation and prioritization
  • Inform biomarker strategy

Traditional

Expert literatureExpert Literature
Mouse model
No faithfulanimal model
Mouse Validation≠Human Mechanism
Wrong
Target
VS
DifferentiaHuman Evidence
Human mechanistic disease model

Human Mechanistic
disease model

Virtual patient perturbation

Virtual Patient
Perturbation

Disease stateHealth homeostasis

AI
Ranking

Optimal Target

Make decisions on human biology, not mice

Preclinical

Best Molecule

Connect candidate-specific properties to human disease biology and compare molecules head to head across exposure, target engagement, efficacy, safety and differentiation.

Compare candidates through human mechanistic simulation

Core Value

  • Integrate all pre-clinical data to simulate human outcome
  • Simulate against competitor therapies
  • Optimize pipeline/portfolio strategy

Relying only on animal data <10% success rate in humans

Traditional

MoleculeMolecule
Mouse
Response
Response
Human
No effective response
No effective response
Validated in mice
≠
Validated in humans
VS

Differentia

Human data inputs

Target engagement
Tissue exposure
Efficacy potential
Therapeutic window
Toxicity

PROGRESSION-FREE SURVIVAL

100%0mPFS 9.4 momPFS 4.1 moTime →
Differentia Candidate ATraditional Candidate B

Simulate and Identify Optimal Molecule in Virtual Patients

Differentiator: A · 9.4mo
Translational

Best Dosing

Connect administered dose to exposure, target engagement, efficacy and safety across diverse virtual patients. Design a treatment strategy around the complete benefit–risk profile.

Simulate all possible strategies before testing on humans

Core Value

  • Inform dose and regimen selection
  • Balance efficacy, safety and exposure
  • Enable precision dosing strategies

Traditional

Empirical
extrapolation

Human equivalent dose

HED = Animal dose × Km, animal / Km, human

Animal
effective doseGAPhuman
starting dose
REGIMEN AEliminated
300 mg QD32%ORR
Grade ≥3 AE34%
Underexposed28%
VS

Differentia

Large-cohort
virtual trial

Virtual patients1,000,000virtual patients
Dosing regimen designs100-500Dosing & regimen designs

Rank every regimen by efficacy, safety and exposure

Regimen B selected
REGIMEN BSelected
150 mg BID58%ORR
Grade ≥3 AE15%
Underexposed9%
Clinical

Best Trial Design & Segmentation

Create virtual cohorts, apply eligibility criteria and treatment strategies, and compare alternative clinical trial designs before execution.

Best Trial Design

Better data, extreme efficiency, higher asset value

Core Value

  • Simulate and differentiate against competitors
  • Reduce 20-60% trial size with regulatory support
  • Faster time to market, additional exclusivity revenue

Virtual Trial optimization

01 Match

Fit-for-purpose
virtual cohort

Large virtual patient population
Smaller fit-for-purpose cohort
Eligibility · disease features · biomarkers
02 Simulate

500+ protocol
scenarios simulation

Protocol AProtocol BProtocol C
Real-time
dataCompetitors
Simulation computer
03 Select

Optimal Trial
design

Endpoint
Patient No.
Risk
Speed
Traditional Differentia
Traditional

Real patients + multiple dose arms

Traditional real-patient cohorts
20–60%Fewer Real PatientsEfficacy&Safety
Differentia

Precise-dose cohorts +
virtual patient substitution

Selected patients+Virtual patient substitution

Best Segmentation

The right segmentation can create a much better clinical outcome signal

Core Value

  • Integrate multi-omics data to simulate mechanistic heterogeneity
  • Enable precision medicine strategies
  • Explainable regulatory grade evidence

Traditional

Patient clustersBlack-box prediction
Black-box
predictionCluster ≠ treatment
benefitRequires a large
sample size
VS

Differentia

Mechanism + Multi-omic data
Disease MOATargetPathwayDrug MoA
Efficacy & safety outcomes
PFSOSORRDoRpCRAE
Input connections to virtual patient simulation
Virtual patient simulation response trajectories
Virtual Patient Simulation
SELECTED FROM SIMULATED RESPONSEBest-fit patient profile
Pathway activeTarget state matchedDrug MoA sensitiveFavorable safety state
RECOMMENDED
ENROLLMENT

The Result: Best Asset

When the five critical decisions work together, they compound into the highest-value outcome.

Probability of successHigher chance of clinical and regulatory success↑
Development timeFaster path to meaningful decision points↓
Clinical costLower trial cost through smarter investment↓
Evidence qualityStronger, more credible, and reusable evidence↑
Commercial valueHigher probability of market success and ROI↑

Ultimately: higher-value assets with higher R&D ROI.

Ready to simulate your next decision?

Let's build better assets together. Powerful science. Proven at scale.

Discuss Your Program